ReviewMolecular Methods and Platforms for Infectious Diseases Testing: A Review of FDA-Approved and Cleared Assays
Under a Creative Commons license
open access
Cited by (0)
R.E. and J.B.B. contributed equally to this work.
Disclosures: R.E., Cepheid stock ownership of <$5000 (July 30, 2010); J.B.B., employee of Life Technologies; R.S., received grants for research, speaker assignments, or scientific advisory board from Eragen, Nanogen, bioMérieux, Gen-Probe Inc., Luminex, Idaho Technologies, BD, and Autogenomics; V.S., previous employee of Chiron Corporation (Novartis) and Digene Corporation (Qiagen); B.L.Z., employee of Siemens Healthcare Diagnostics; M.M.S., employee of Cepheid; and P.P., received grants from Qiagen, Cepheid, Abbott, and Primera.
Disclaimer: The findings and conclusions herein are those of the author (L.W.) and do not necessarily represent the official position of the CDC.
Copyright © 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc.